CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
Open Access
- 2 November 2010
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (11) , 1671-1679
- https://doi.org/10.1038/sj.bjc.6605968
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 50 references indexed in Scilit:
- Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancerInternational Journal of Cancer, 2009
- EGF-Induced ERK Activation Promotes CK2-Mediated Disassociation of α-Catenin from β-Catenin and Transactivation of β-CateninMolecular Cell, 2009
- FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating AktCancer Cell, 2009
- Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and AktInternational Journal of Cancer, 2009
- Pancreatic cancer: molecular pathogenesis and new therapeutic targetsNature Reviews Gastroenterology & Hepatology, 2009
- High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinomaBritish Journal of Cancer, 2009
- CXCL8/IL‐8 and CXCL12/SDF‐1α co‐operatively promote invasiveness and angiogenesis in pancreatic cancerInternational Journal of Cancer, 2008
- Chemokines in tumor angiogenesis and metastasisCancer and Metastasis Reviews, 2007
- Mitogenic signaling pathways induced by G protein‐coupled receptorsJournal of Cellular Physiology, 2007
- Phosphorylation of β-Catenin by AKT Promotes β-Catenin Transcriptional ActivityJournal of Biological Chemistry, 2007